Biogen on Thursday reported higher-than-expected fourth-quarter profit on strong demand for its oral multiple sclerosis drug Tecfidera.» Read More
Biogen Idec's anti-LINGO-1, showed promise in a mid-stage study in reversing the nerve damage associated with acute optic neuritis.
A new family of powerful antibiotics may provide a weapon against the growing threat of drug-resistant superbugs. NBC News reports.
This year’s flu season is shaping up to be as bad as expected. That's good news for drug stores, but insurers and others could suffer.
Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic.
A new drug activates receptors in the intestine, tricking the body into thinking it has just eaten a meal.
Gilead Sciences' hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS/Caremark.
Despite drug pricing concerns that weighed on Gilead Sciences' stock toward the end of December, the drugmaker started the year by raising prices.
Rather than pay so much out-of-pocket, many skip checkups and scrimp on care, USA Today reports.
Express Scripts says its largest plan will cover only AbbVie's hepatitis C regimen, excluding drugs from Gilead and J&J.
This flu season is ramping up earlier than last year's, NBC News reports.
Hallucinogenic mushrooms have been discovered on the grounds of Buckingham Palace in London, NBC News reports.
Infections resistant to medicine will kill more people per year than cancer, and cost the world $100 trillion annually by 2050, according to a report.
Philadelphia's transit agency has filed a lawsuit against Gilead Sciences challenging the "exorbitant pricing" of its hepatitis C drug Sovaldi.
As 2014's trading days dwindle, some traders are turning toward small cap stocks in hopes of boosting their portfolio returns.
Discovering and developing new treatments for diseases is notoriously expensive, but now it could be becoming slightly more financially rewarding.
Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.
Celgene's partnering strategy, which has accelerated in recent years, is starting to bear fruit; many of the most-watched stocks out of ASH fall under its umbrella.
Three small-cap drug firms are consistently the best biotech performers following the start of the American Society of Hematology's annual meeting.
Doctors who used Genentech's expensive eye drug Lucentis were also among the highest-paid consultants for the company, reports the New York Times.
CNBC's Meg Tirrell reports on hottest new technologies from the annual meeting of the American Society of Hematology.
Get the best of CNBC in your inbox